Regulation of Med1 protein by overexpression of BAP1 in breast cancer cells

References

• Ito M, Roeder RG. The TRAP/SMCC/Mediator complex and thyroid hormone receptor function. Trend Endocrinol Metabol. 2001;12(3):127–7. doi:10.1016/S1043-2760(00)00355-6.
   PubMed Web of Science ®Google Scholar
• Zhang X, Krutchinsky A, Fukuda A, Chen W, Yamamura S, Chait BT, Roeder RG. MED1/TRAP220 exists predominantly in a TRAP/Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. Mol Cell. 2005;19(1):89–100. doi:10.1016/j.molcel.2005.05.015.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Qi C, Jain S, Le Beau MM, Espinosa R, Atkins GB, Lazar MA, Yeldandi AV, Rao MS, Reddy JK. Amplification and overexpression of peroxisome proliferator activated receptor binding protein (PBP/PPARBP) gene in breast cancer. Proc Natl Acad Sci USA. 1999;96(19):10848–10853. doi:10.1073/pnas.96.19.10848.
   PubMed Web of Science ®Google Scholar
• Leonard M, Zhang X. Estrogen receptor coactivator mediator subunit 1 (MED1) as a tissue-specific therapeutic target in breast cancer. J Zhejiang Univ-sc B. 2019;20:381–390.
   PubMed Web of Science ®Google Scholar
• Frade R, Balbo M, Barel M. RB18A regulates p53-dependent apoptosis. Oncogene. 2002;21(6):861–866. doi:10.1038/sj.onc.1205177.
   PubMed Web of Science ®Google Scholar
• Jin F, Irshad S, Yu W, Belakavadi M, Chekmareva M, Ittmann MM, Abate-Shen C, Fondell JD. ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity MED1 overexpression in prostate cancer. Mol Cancer Res. 2013;11(7):736–747. doi:10.1158/1541-7786.MCR-12-0618.
   PubMed Web of Science ®Google Scholar
• Ndong J, Jean D, Rousselet N, Frade R. Down‐regulation of the expression of RB18A/MED1, a cofactor of transcription, triggers strong tumorigenic phenotype of human melanoma cells. Int J Cancer. 2009;124(11):2597–2606. doi:10.1002/ijc.24253.
   PubMed Web of Science ®Google Scholar
• Kim H-J, Roh MS, Son CH, Kim AJ, Jee HJ, Song N, Kim M, Seo S-Y, Yoo YH, Yun J. et al. Loss of Med1/TRAP220 promotes the invasion and metastasis of human non-small-cell lung cancer cells by modulating the expression of metastasis-related genes. Cancer Lett. 2012;321(2):195–202. doi:10.1016/j.canlet.2012.02.009.
   PubMed Web of Science ®Google Scholar
• Klümper N, Syring I, Vogel W, Schmidt D, Müller SC, Ellinger J, Adler D, Brägelmann J, Perner S. Mediator complex subunit MED1 protein expression is decreased during bladder cancer progression. Front Med. 2017;4:30. doi:10.3389/fmed.2017.00030.
   Web of Science ®Google Scholar
• Swatek KN, Komander D. Ubiquitin modifications. Cell Res. 2016;26(4):399–422. doi:10.1038/cr.2016.39.
   PubMed Web of Science ®Google Scholar
• Sun T, Liu Z, Yang Q. The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer. 2020;19(1):1–19. doi:10.1186/s12943-020-01262-x.
   PubMed Web of Science ®Google Scholar
• He M, Zhou Z, Shah AA, Zou H, Tao J, Chen Q, Wan Y. The emerging role of deubiquitinating enzymes in genomic integrity, diseases, and therapeutics. Cell & Biosci. 2016;6(1):1–15. doi:10.1186/s13578-016-0127-1.
   PubMedGoogle Scholar
• Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y. et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 1998;16(9):1097–1112. doi:10.1038/sj.onc.1201861.
   PubMed Web of Science ®Google Scholar
• Mashtalir N, Daou S, Barbour H, Sen NN, Gagnon J, Hammond-Martel I, Dar H, Therrien M, Affar E. Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O. Mol Cell. 2014;54(3):392–406. doi:10.1016/j.molcel.2014.03.002.
   PubMed Web of Science ®Google Scholar
• Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410–1413. doi:10.1126/science.1194472.
   PubMed Web of Science ®Google Scholar
• Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022–1025. doi:10.1038/ng.912.
   PubMed Web of Science ®Google Scholar
• Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P. et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44(7):751–759. doi:10.1038/ng.2323.
   PubMed Web of Science ®Google Scholar
• Wang L, Birch NW, Zhao Z, Nestler CM, Kazmer A, Shilati A, Blake A, Ozark PA, Rendleman EJ, Zha D. et al. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia. Nat Cancer. 2021;2(5):515–526. doi:10.1038/s43018-021-00199-4.
   PubMedGoogle Scholar
• Qin J, Zhou Z, Chen W, Wang C, Zhang H, Ge G, Shao M, You D, Fan Z, Xia H. et al. BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5. Nat Commun. 2015;6(1):1–12. doi:10.1038/ncomms9471.
   Google Scholar
• Liu Z, Meray RK, Grammatopoulos TN, Fredenburg RA, Cookson MR, Liu Y, Logan T, Lansbury PT. Membrane-associated farnesylated UCH-L1 promotes α-synuclein neurotoxicity and is a therapeutic target for Parkinson’s disease. Proc Natl Acad Sci USA. 2009;106(12):4635–4640. doi:10.1073/pnas.0806474106.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lashuel HA, Choi S, Xing X, Case A, Ni J, Yeh L-A, Cuny GD, Stein RL, Lansbury PT. et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol. 2003;10(9):837–846. doi:10.1016/j.chembiol.2003.08.010.
   PubMed Web of Science ®Google Scholar
• Gade P, Singh AK, Roy SK, Reddy SP, Kalvakolanu DV. Down‐regulation of the transcriptional mediator subunit Med1 contributes to the loss of expression of metastasis‐associated dapk1 in human cancers and cancer cells. Int J Cancer. 2009;125(7):1566–1574. doi:10.1002/ijc.24493.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, Wang Q. Phospho‐MED1‐enhanced UBE2C locus looping drives castration‐resistant prostate cancer growth. Embo J. 2011;30(12):2405–2419. doi:10.1038/emboj.2011.154.
   PubMed Web of Science ®Google Scholar
• Rasool R RU, Natesan R, Deng Q, Aras S, Lal P, Effron SS, Mitchell-Velasquez E, Posimo JM, Carskadon S, Baca SC. et al. CDK7 inhibition suppresses castration-resistant prostate cancer through MED1 inactivation. Cancer Discov. 2019;9(11):1538–1555. doi:10.1158/2159-8290.CD-19-0189.
   PubMed Web of Science ®Google Scholar
• Belakavadi M, Pandey PK, Vijayvargia R, Fondell JD. MED1 phosphorylation promotes its association with mediator: implications for nuclear receptor signaling. Mol Cell biol. 2008;28(12):3932–3942. doi:10.1128/MCB.02191-07.
   PubMed Web of Science ®Google Scholar
• Jia Y, Viswakarma N, Reddy JK. Med1 subunit of the mediator complex in nuclear receptor-regulated energy metabolism, liver regeneration, and hepatocarcinogenesis. Gene Expr. 2014;16(2):63. doi:10.3727/105221614X13919976902219.
   PubMed Web of Science ®Google Scholar
• Schiano C, Rienzo M, Casamassimi A, Napoli C. Gene expression profile of the whole mediator complex in human osteosarcoma and normal osteoblasts. Med Oncol. 2013;30(4):1–6. doi:10.1007/s12032-013-0739-9.
   Web of Science ®Google Scholar
• Jiang C, Chen H, Shao L, Wang Q. MicroRNA-1 functions as a potential tumor suppressor in osteosarcoma by targeting Med1 and Med31. Oncol Rep. 2014;32(3):1249–1256. doi:10.3892/or.2014.3274.
   PubMed Web of Science ®Google Scholar
• Blatnik A, Ribnikar D, Šetrajčič Dragoš V, Novaković S, Stegel V, Grčar Kuzmanov B, Boc N, Perić B, Škerl P, Klančar G. et al. BAP1-deficient breast cancer in a patient with BAP1 cancer syndrome. Emerg Cancer Ther. 2022;29(5):921–927. doi:10.1007/s12282-022-01354-0.
   Google Scholar
• Shah R. Pathogenesis, prevention, diagnosis, and treatment of breast cancer. World J Clin Oncol. 2014 Aug 8;5(3):283. doi:10.5306/wjco.v5.i3.283.
   PubMedGoogle Scholar
• Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010 Jan;11(1):23–36. doi:10.1038/nrm2821.
   PubMed Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019 Jan 22;321(3):288–300. doi:10.1001/jama.2018.19323.
   PubMed Web of Science ®Google Scholar